Ochre Codon: Stop Codon Function Explained

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-19

The ochre codon is the RNA triplet UAA, one of the three standard stop codons that terminate protein synthesis. Unlike every other codon in the genetic code, UAA is not read by a transfer RNA. It is recognized by a class I release factor, which enters the ribosomal A site and triggers hydrolysis of the finished polypeptide from the tRNA in the P site.

That single fact explains most of what makes stop codons interesting. The ribosome is a decoding machine built around codon-anticodon pairing, yet termination works by protein recognition rather than base pairing. When that recognition fails, translation continues past the stop signal and produces an abnormally extended protein. When a stop codon appears too early in a coding sequence, the ribosome stops short and releases a truncated, usually nonfunctional fragment. Both failure modes matter in human genetics.

Why the Ochre Codon Matters

Roughly one in five disease-causing single-base changes in human genes creates a premature stop codon. These premature termination codons, or PTCs, are collectively implicated in about 1,800 human genetic diseases [1]. The ochre codon is the most common of the three stop signals in many genomes, so it is also the most frequent PTC produced by random mutation of a sense codon. Understanding how UAA is recognized, how faithfully that recognition is enforced, and how it can be bypassed is central to molecular medicine.

The Three Stop Codons and Their Names

The standard genetic code uses three termination triplets: UAA, UAG, and UGA. Each has a historical color name, assigned decades before anyone understood the mechanism.

The color names come from the laboratories and strains where the first nonsense suppressors were isolated. Amber was named after the surname of a researcher's colleague, and ochre and opal were coined later to complete the set. The naming is arbitrary. What matters is the sequence and the biology.

How Ochre Termination Works

Termination is a multistep event that depends on the ribosome reaching the last codon of an open reading frame with the correct factors nearby.

1. The ribosome translocates along the mRNA until a stop triplet occupies the A site. At that point there is no aminoacyl-tRNA in the cell whose anticodon matches UAA, UAG, or UGA in a way that supports peptide bond formation.
2. A class I release factor binds the A site. In eukaryotes this is eRF1, which structurally mimics a tRNA and reads the stop codon directly [1]. In bacteria the equivalent is RF1 or RF2, and in mitochondria the factors are mtRF1 and mtRF1L [4].
3. A class II release factor (eRF3 in eukaryotes) delivers the class I factor to the ribosome in a GTP-dependent manner and stimulates the reaction.
4. The class I factor carries a conserved GGQ motif that reaches into the peptidyl transferase center and positions a water molecule to hydrolyze the ester bond linking the polypeptide to the P-site tRNA.
5. The completed protein is released, and the ribosome is recycled by additional factors so it can begin a new round of translation.

The key mechanistic point is that codon recognition in termination is performed by protein, not RNA. Release factors have structural elements that contact the stop codon in the A site and discriminate it from sense codons. This is why no tRNA is needed and why the process is sometimes called codon-dependent but tRNA-independent termination.

flowchart TD
    A[Ribosome reaches stop codon] --> B{Codon in A site}
    B --> C[UAA ochre]
    B --> D[UAG amber]
    B --> E[UGA opal]
    C --> F[Release factor binds]
    D --> F
    E --> F
    F --> G[GGQ motif hydrolyzes peptide]
    G --> H[Protein released]
    H --> I[Complex recycled]
    F --> J[Near cognate tRNA competes]
    J --> K[Readthrough and extension]

Why Ochre Is Not Read by tRNA

Students often assume that every codon has a matching tRNA. That is true for the 61 sense codons, but not for the three stop codons. Cells do not maintain tRNAs with anticodons complementary to UAA, UAG, or UGA under normal conditions. Instead, the A site of the ribosome is sampled by release factors that can read the stop triplet and by near-cognate tRNAs whose anticodons are close to but not identical to the stop codon.

This competition between release factors and near-cognate tRNAs is the basis of stop codon readthrough. When a near-cognate tRNA wins the race, it inserts an amino acid and elongation continues into what should have been the 3' untranslated region. The result is a C-terminally extended protein. Readthrough is usually inefficient, but it can be regulated, and it can be exploited therapeutically.

Ochre Versus Amber and Opal

All three stop codons share the same basic mechanism, but they differ in several practical ways.

Sequence. UAA, UAG, and UGA differ at the second and third positions. UAA and UAG share the first two bases, while UGA has a guanine at position two. Because release factor recognition depends on the exact triplet, the three codons are not interchangeable in every context.

Frequency. In many genomes UAA is the most frequently used stop codon, though the distribution varies by organism and by gene. Codon usage bias in stop codons is real and is shaped by the availability of release factors and by selection for efficient termination.

Readthrough susceptibility. Different stop codons are read through at different rates. UGA is often the most readthrough-prone in eukaryotic systems, and UAG readthrough is well documented in specific contexts. UAA is generally the most efficient terminator, which is one reason it is common at the ends of highly expressed genes.

Context dependence. Readthrough depends heavily on the nucleotides immediately surrounding the stop codon, collectively called the stop codon context [5][6]. The +4 position, the +4 to +9 window, and even positions as far as -9 and +11 have measurable effects on termination efficiency [7][6]. A UAA in a poor context can be read through more often than a UGA in a strong context.

Premature Ochre Codons and Disease

A premature ochre codon arises when a point mutation converts a sense codon into UAA. The consequences depend on where the mutation lands.

Beta-thalassemia. Nonsense mutations in the HBB gene, including ochre codons, reduce or eliminate beta-globin production. The truncated globin chain cannot assemble into functional hemoglobin, and the transcript is often degraded by nonsense-mediated mRNA decay.

Duchenne muscular dystrophy. Nonsense mutations in the DMD gene introduce premature stop codons, including ochre, that truncate dystrophin. Readthrough compounds such as negamycin derivatives have been evaluated against DMD and congenital muscular dystrophy nonsense sequences in cell-based reporter assays [8].

Cystic fibrosis. Nonsense variants in CFTR account for roughly 10 percent of CF variants and cannot be treated with available CFTR modulators [3]. Ochre and other PTCs in CFTR are targets for readthrough agents, and patient-derived intestinal organoids have been used to test responses across a wide range of variants [3].

Cancer. In BRCA2-mutated ovarian cancer, acquired resistance to PARP inhibitors and cisplatin has been linked to low-level readthrough of a UAG PTC that restores full-length BRCA2 protein [2]. This shows that readthrough is not only a therapeutic target but also a mechanism of drug resistance.

Hemophilia A. Nonsense mutations in F8 vary widely in their association with inhibitor development after replacement therapy. Readthrough output and the resulting wild-type protein traces appear to influence the immune response [9].

The unifying theme is that a premature ochre codon usually produces a truncated protein, and the severity of disease depends on how much functional protein is needed and how much can be restored by residual readthrough or by therapy.

How Termination and Readthrough Are Measured

Several experimental approaches are used to study ochre codon function.

Reporter assays. Dual-fluorescence or luciferase reporters place a stop codon between two reporter genes. Readthrough produces a fusion protein whose activity is proportional to the readthrough rate. This approach has been used to map the effects of stop codon identity and downstream sequence on readthrough [7][6].

Ribosome profiling. Deep sequencing of ribosome-protected fragments reveals where ribosomes pause and where they continue past a stop codon. Ribosome profiling has been used to show that glutamine codon context and global glutamine codon content influence readthrough efficiency in yeast [10].

Mass spectrometry. Direct detection of the amino acid inserted at a stop codon confirms the identity of the readthrough product. Mass spectrometry has been used to show that glutamine is specifically inserted at premature stops in yeast, with no flanking miscoding [10].

Patient-derived organoids. Intestinal organoids from cystic fibrosis patients carrying different nonsense variants have been used to quantify functional rescue after exposure to readthrough agents [3].

Saturation genome editing. Systematic introduction of all possible PTCs at every codon position in a gene, combined with NMD inhibition, allows quantitative measurement of mRNA expression and NMD activity for hundreds of variants at once [11].

Readthrough Drugs and Their Context Dependence

Readthrough agents are small molecules that reduce termination fidelity and allow near-cognate tRNAs to decode stop codons. They include aminoglycosides such as G418, the synthetic compound ataluren, and newer agents such as ELX-02 and 2,6-diaminopurine.

The central lesson from recent work is that readthrough is highly context dependent. ELX-02 rescue varied markedly across 206 patient-derived organoids carrying heterogeneous CFTR nonsense variants, ranging from responses approaching approved CFTR modulators to responses at or below the detection limit [3]. Aminoglycoside-induced readthrough depends on the expanded stop codon context, including positions far upstream and downstream of the stop codon, and these effects are non-linear and not always transferable between species [6].

Different compounds also have different sequence preferences. The negamycin derivative TCP-306 showed potent readthrough against TGA-A sequences, while G418 preferentially induced readthrough at TGA-C sequences [8]. This means a drug that works well for one nonsense allele may work poorly for another, and variant-specific testing is essential.

Readthrough also interacts with nonsense-mediated mRNA decay. Many PTC-containing transcripts are degraded before they can be translated, so readthrough efficiency depends on how much mRNA survives [11][12]. Combining readthrough agents with NMD inhibition has been explored as a strategy to increase rescue, though the therapeutic window is narrow.

Common Mistakes and Limitations

Assuming every codon has a tRNA. Stop codons do not. Termination is mediated by release factors, and this is the single most important distinction between stop codons and sense codons.

Treating the three stop codons as interchangeable. UAA, UAG, and UGA differ in frequency, readthrough susceptibility, and context sensitivity. A mutation that changes one stop codon to another can alter termination efficiency.

Ignoring context. The nucleotides around a stop codon strongly influence readthrough. A stop codon in a poor context may terminate inefficiently even without a drug.

Confusing readthrough with suppression. Nonsense suppression in bacteria involves mutant tRNAs that read stop codons. Readthrough in eukaryotes typically involves near-cognate tRNAs competing with release factors. The mechanisms overlap but are not identical.

Overestimating drug effects. Readthrough agents typically restore only a fraction of normal protein levels, and responses vary widely by variant [3]. Clinical benefit depends on how much functional protein is needed.

Forgetting NMD. Many PTC-containing transcripts are degraded, so the amount of protein produced by readthrough depends on mRNA stability as well as translation.

Individual cases require clinical evaluation. The general principles here do not predict the outcome for a specific patient or variant.

Quick Review

• The ochre codon is UAA, one of three stop codons.
• Stop codons are read by release factors, not tRNAs.
• eRF1 recognizes the stop codon in eukaryotes, and eRF3 stimulates the reaction.
• UAA is the most frequent stop codon in many genomes.
• Premature ochre codons cause truncated proteins in diseases such as beta-thalassemia and Duchenne muscular dystrophy.
• Readthrough occurs when a near-cognate tRNA outcompetes the release factor.
• Readthrough efficiency depends on stop codon identity, surrounding sequence, and mRNA stability.

The Ribosome as a Decoding Machine: Where Termination Fits

To understand why the ochre codon behaves the way it does, it helps to separate translation into its two chemically distinct phases. During elongation, the ribosome performs a repetitive catalytic cycle: an aminoacyl-tRNA is delivered to the A site as a ternary complex with elongation factor Tu (in bacteria) or eEF1A (in eukaryotes), codon-anticodon pairing is proofread, a peptide bond is formed in the peptidyl transferase center, and the ribosome translocates by one triplet. Every step in that cycle is driven by RNA-RNA complementarity and by the accommodation of an RNA adaptor into a catalytic RNA machine.

Termination breaks that pattern. There is no aminoacyl-tRNA to deliver, no peptide bond to form, and no translocation to perform. Instead, the ribosome must switch from a synthetic mode to a hydrolytic mode. The same catalytic center that normally joins an amino acid to a growing chain is repurposed to attach a water molecule to the ester bond between the polypeptide and the P-site tRNA. The ochre codon is the signal that flips this switch.

This is why the ochre codon is best understood not as "the absence of a sense codon" but as a positive recognition signal. The ribosome does not simply stall at UAA and wait for something to happen. A release factor actively reads the triplet, and that reading event is what commits the ribosome to hydrolysis. If you remove the release factor, the ribosome does not terminate efficiently at UAA; it tends to pause and then either resume elongation or stall. Termination is an active, factor-dependent decision, not a passive default.

A Worked Example: Following a Single Ochre Codon Through the Ribosome

Consider a hypothetical short open reading frame in a eukaryotic mRNA with the sequence AUG-AAA-GGU-UAA-... The ribosome initiates at AUG, elongates through AAA (lysine) and GGU (glycine), and then encounters UAA in the A site. Walking through the events step by step makes the mechanism concrete.

Step 1: A-site occupancy. After translocation, the P site holds the peptidyl-tRNA carrying the dipeptide Lys-Gly, and the A site is empty but positioned over UAA. The mRNA is held in place by the codon-anticodon interaction in the P site and by the ribosome's mRNA channel.

Step 2: Sampling. The A site is sampled by whatever ternary complexes are abundant in the cytoplasm. No cognate tRNA exists for UAA, so the only productive binding event is with eRF1, delivered as a ternary complex with eRF3 and GTP. Near-cognate tRNAs, such as a tRNA whose anticodon differs from UAA by one base, can also attempt to bind, and this is the origin of readthrough.

Step 3: Codon recognition by eRF1. eRF1 inserts a structural domain into the A site that makes direct contacts with the UAA triplet. The recognition is shape-complementary rather than base-pairing, and it discriminates UAA from sense codons using a combination of hydrogen bonding and steric exclusion. This is the step that defines ochre specificity.

Step 4: GTP hydrolysis and conformational change. eRF3 hydrolyzes GTP, which drives a conformational rearrangement that locks eRF1 into the A site and positions its GGQ motif near the peptidyl transferase center.

Step 5: Peptide hydrolysis. The GGQ motif coordinates a water molecule and orients it for attack on the ester bond linking the polypeptide to the P-site tRNA. The polypeptide is released.

Step 6: Recycling. eRF1 remains bound briefly, then the ribosome is split into subunits by ABCE1 and additional recycling factors so that the mRNA, tRNAs, and subunits can be reused.

If you substitute UAG or UGA for UAA at step 1, the same pathway runs with the same factors, but the affinity and kinetics of recognition differ. That difference is the molecular basis for the observation that UAA is generally the most efficient terminator.

The Structural Logic of Stop Codon Recognition

Release factor recognition of stop codons is one of the more elegant examples of molecular mimicry in biology. eRF1 adopts a tRNA-like overall shape, with a domain that occupies the A site in a manner analogous to an anticodon loop. However, the chemical details are entirely different. Where a tRNA uses Watson-Crick hydrogen bonds between its anticodon and the codon, eRF1 uses a set of conserved residues that read the triplet through a combination of hydrogen bonding and shape complementarity.

The discrimination problem is nontrivial. The stop codons UAA, UAG, and UGA must be distinguished from 61 sense codons, several of which differ from a stop codon by a single base. For example, UAC (tyrosine) differs from UAA at the third position, and UUA (leucine) differs from UAA at the second position. eRF1 must reject these near-cognates while accepting the three stop codons. Structural and biochemical work has shown that the recognition surface is tuned to the specific functional groups presented by the stop triplets, and that mutations in the recognition domain can relax specificity and permit readthrough of sense codons.

Bacteria solve the same problem with two factors rather than one. RF1 recognizes UAA and UAG, while RF2 recognizes UAA and UGA. The overlap at UAA means that ochre is read by both bacterial factors, which may contribute to its efficiency as a terminator. Mitochondria use a different set of factors again, including mtRF1 and mtRF1L, reflecting the divergent genetic codes found in some mitochondrial lineages [4].

Context Effects: Why the Same Ochre Codon Behaves Differently in Different Genes

One of the most practically important facts about the ochre codon is that its behavior is not determined by the triplet alone. The nucleotides surrounding the stop codon, collectively called the stop codon context, modulate termination efficiency and readthrough rate. This has been demonstrated repeatedly using reporter assays and ribosome profiling.

The +4 position, immediately 3' of the stop codon, is the most studied context element. Certain bases at +4 favor efficient termination, while others favor readthrough. The effect extends further: positions from roughly -9 to +11 have been shown to influence readthrough, and the effects are non-linear and can interact with each other [7][6]. This means that two genes with identical ochre codons can terminate with different efficiencies if their surrounding sequences differ.

Several mechanisms contribute to context effects. The mRNA sequence downstream of the stop codon can influence how the mRNA sits in the ribosome's channel, which in turn affects how easily a release factor or a near-cognate tRNA can access the A site. The context can also affect the stability of the mRNA itself, since sequences near the stop codon can influence nonsense-mediated decay. Finally, context can affect the local structure of the mRNA, and structured regions can slow ribosome movement and change the kinetics of the termination decision.

For anyone interpreting a variant or designing a readthrough experiment, the practical implication is that context must be considered alongside the stop codon identity. A UAA in a permissive context may be a poor candidate for readthrough therapy, while a UAA in a restrictive context may respond better than expected.

Readthrough in Detail: The Kinetic Competition Model

Readthrough is best understood as a kinetic competition at the A site. When the ribosome reaches a stop codon, two classes of ligands can potentially occupy the A site: release factors and near-cognate aminoacyl-tRNAs. Whichever binds productively first determines the outcome. If a release factor wins, the protein is terminated. If a near-cognate tRNA wins, an amino acid is inserted and elongation continues.

Several factors shift the balance.

Release factor availability. If release factor levels are limiting, readthrough increases. This has been observed in cells where release factor expression is reduced.

Near-cognate tRNA abundance. The more abundant a near-cognate tRNA is, the more likely it is to compete successfully. This is why global tRNA pool composition affects readthrough rates, and why codon content elsewhere in the genome can influence readthrough at a specific stop codon [10].

Stop codon identity. Different stop codons are read by different release factors with different affinities, and they are also decoded by different sets of near-cognate tRNAs. UGA is often the most readthrough-prone in eukaryotes because it is decoded by tryptophan and cysteine near-cognates, while UAA and UAG are decoded by glutamine and tyrosine near-cognates.

Context. As discussed above, the surrounding sequence affects the accessibility of the A site and the kinetics of the decision.

mRNA stability. If the transcript is degraded by nonsense-mediated decay before translation completes, readthrough cannot occur. Conversely, if NMD is inhibited, more transcript is available for readthrough [11][12].

The kinetic competition model explains why readthrough is usually inefficient. Under normal conditions, release factors are abundant and well adapted to their codons, so they usually win. Readthrough becomes significant only when the balance is shifted, either by a drug, by reduced release factor availability, or by an unusually permissive context.

Nonsense-Mediated Decay and the Ochre Codon

A premature ochre codon does not act in isolation. In eukaryotes, transcripts containing premature termination codons are often targeted for degradation by nonsense-mediated mRNA decay, a quality control pathway that reduces the production of truncated proteins. The pathway is triggered by the presence of an exon junction complex downstream of the stop codon, which is interpreted as a signal that termination occurred prematurely.

The relationship between NMD and the ochre codon has practical consequences. First, it means that the amount of truncated protein produced from a PTC-containing allele is often lower than the mRNA level would suggest, because the transcript is degraded. Second, it means that readthrough efficiency depends on how much mRNA survives NMD. Third, it means that inhibiting NMD can increase the amount of protein produced by readthrough, which is why combinations of readthrough agents and NMD inhibitors have been explored [11][12].

NMD also complicates the interpretation of reporter assays. A reporter construct may not recapitulate the NMD sensitivity of the endogenous gene, so readthrough rates measured in a reporter may not predict the response in a patient cell. This is one reason patient-derived models such as intestinal organoids are valuable for testing readthrough agents [3].

Comparing the Three Stop Codons in Practice

The table in the main article lists the three stop codons and their aliases. For practical work, several additional distinctions matter.

Termination efficiency. UAA is generally the most efficient terminator, followed by UAG, with UGA often the least efficient in eukaryotic systems. This ordering is not absolute and depends on context and organism.

Readthrough susceptibility. UGA is often the most readthrough-prone, which is why it is frequently used in programmed readthrough contexts and why UGA nonsense variants are sometimes considered more amenable to readthrough therapy. UAA is generally the least readthrough-prone.

Codon usage. UAA is the most frequent stop codon in many genomes, though the distribution varies. Highly expressed genes often use UAA, which is consistent with its role as an efficient terminator.

Disease associations. All three stop codons can be created by mutation, and all three are found in human disease. The specific codon matters for prognosis and for therapy selection, because readthrough agents have different preferences for different stop codons and contexts [8].

Practical Applications: Where Ochre Codon Biology Is Used

Ochre codon biology is not only a topic for textbooks. It has direct applications in several areas of research and medicine.

Variant interpretation. When a clinical variant creates a premature ochre codon, the expected consequence is a truncated protein, often with reduced function and reduced mRNA stability. Knowing the codon identity and context helps predict severity and guides functional testing.

Readthrough therapy development. Compounds that promote readthrough are being developed for diseases caused by nonsense mutations, including cystic fibrosis, Duchenne muscular dystrophy, and certain cancers. Because responses vary widely by variant, testing is done in patient-derived models rather than assuming a class effect [3][8].

Cancer drug resistance. Readthrough of a PTC in BRCA2 has been linked to acquired resistance to PARP inhibitors and cisplatin in ovarian cancer [2]. This means that readthrough is not only a therapeutic target but also a mechanism that can undermine therapy, and it argues for monitoring readthrough in patients on these drugs.

Vaccine and antigen design. Understanding stop codon context and readthrough helps in designing expression constructs, since unintended readthrough can produce extended proteins with altered immunogenicity.

Basic research on translation. The ochre codon is a tool for studying termination, readthrough, and ribosome recycling. Reporter constructs with UAA in defined contexts allow precise measurement of termination efficiency and the effects of trans-acting factors.

Troubleshooting Common Experimental Problems

Researchers working with ochre codons and readthrough often encounter predictable problems. A few practical notes.

Unexpected readthrough in control constructs. If a control reporter shows readthrough, check the stop codon context. A permissive context can produce baseline readthrough even without a drug. Also check for near-cognate tRNA abundance in the host cell, since different cell lines have different tRNA pools.

Variable responses across variants. If a readthrough agent works in one construct but not another, the difference may be context rather than the drug. Test the same stop codon in different contexts to separate the effects.

Reporter assays that do not predict patient responses. Reporter constructs may lack the NMD sensitivity and context of the endogenous gene. Use patient-derived cells or organoids when possible, and interpret reporter data as a first pass rather than a final answer [3].

Confounding by NMD. If readthrough appears low, check whether the transcript is being degraded by NMD. Inhibiting NMD can reveal readthrough that was masked by transcript loss [11][12].

Species differences. Readthrough effects observed in yeast or in cell lines may not transfer to human cells, because release factor levels, tRNA pools, and context preferences differ [6]. Validate in the relevant system.

Common Misconceptions Revisited

Several misconceptions about the ochre codon come up repeatedly in teaching and in the literature.

Misconception: The ochre codon is "silent" or "empty." In fact, UAA is a positive signal that is actively recognized by release factors. It is not the absence of information; it is a specific instruction.

Misconception: All stop codons are equivalent. They differ in frequency, readthrough susceptibility, context sensitivity, and disease associations. Treating them as interchangeable can lead to incorrect predictions.

Misconception: Readthrough is always a defect. In some contexts, readthrough is regulated and functional, and in others it is a mechanism of drug resistance. It is not inherently pathological.

Misconception: A readthrough drug will fix any nonsense mutation. Responses vary widely by variant and context, and many variants respond poorly [3]. Readthrough is a partial and variant-specific effect.

Misconception: NMD is irrelevant to readthrough. NMD determines how much mRNA is available for readthrough, so it directly affects the outcome [11][12].

Putting It Together: A Decision Framework for Ochre Codon Variants

When you encounter a premature ochre codon in a gene of interest, a structured approach helps.

First, confirm the variant and its context. Identify the exact position, the surrounding sequence, and whether the codon is UAA, UAG, or UGA. Note the +4 position and the broader context window.

Second, assess the expected consequence. A premature ochre codon is expected to truncate the protein and may trigger NMD. The severity depends on where the codon falls and how much functional protein is needed.

Third, consider readthrough potential. UAA is generally the least readthrough-prone, but context can override this. If readthrough is a therapeutic option, test in a relevant model rather than assuming a class effect.

Fourth, account for NMD. If the transcript is NMD-sensitive, readthrough efficiency will depend on mRNA survival. Consider whether NMD inhibition is part of the therapeutic strategy.

Fifth, validate in the relevant system. Reporter assays, cell lines, and patient-derived models each have limitations. Use the model that best reflects the clinical context [3].

This framework does not replace clinical judgment, and individual cases require evaluation by qualified professionals. But it provides a structured way to think about ochre codon variants and their consequences.

Summary of Key Mechanistic Points

The ochre codon is UAA, one of three stop codons. It is recognized by class I release factors rather than tRNAs, and this protein-based recognition is what triggers hydrolysis of the completed polypeptide. In eukaryotes, eRF1 reads the stop codon and eRF3 stimulates the reaction; in bacteria, RF1 and RF2 share the task, with both recognizing UAA. Mitochondria use their own factors [4].

Termination efficiency and readthrough susceptibility depend on the stop codon identity, the surrounding context, the availability of release factors and near-cognate tRNAs, and the stability of the mRNA. Premature ochre codons cause truncated proteins and are implicated in many genetic diseases, including beta-thalassemia, Duchenne muscular dystrophy, and cystic fibrosis [3]. Readthrough can partially restore full-length protein, but responses vary widely by variant and context, and readthrough can also contribute to drug resistance in cancer [2].

Understanding the ochre codon means understanding that termination is an active, factor-dependent process, that context matters as much as the triplet itself, and that the boundary between termination and readthrough is a kinetic competition that can be shifted by drugs, by sequence, and by the cellular environment.

Frequently Asked Questions

What is the ochre codon?

The ochre codon is the RNA triplet UAA. It is one of the three standard stop codons and signals the end of translation.

Why is UAA called ochre?

The name is historical. It was assigned during early nonsense suppressor studies to distinguish UAA from amber (UAG) and opal (UGA).

Do stop codons have tRNAs?

No. Under normal conditions, stop codons are recognized by release factors rather than tRNAs. Near-cognate tRNAs can occasionally read them, which causes readthrough.

What happens if a premature ochre codon appears in a gene?

The ribosome terminates early and releases a truncated protein. The transcript may also be degraded by nonsense-mediated mRNA decay.

Can readthrough drugs fix premature stop codons?

They can partially restore full-length protein, but responses vary widely by variant, stop codon identity, and surrounding sequence [3]. They are not a universal fix.

Is ochre more common than amber or opal?

UAA is the most frequent stop codon in many genomes, though the distribution varies by organism and gene.

Related Articles

• Stop Codon: Definition, Function, and Role in Translation
• Termination Codon: The Stop Signal in Protein Synthesis
• codon biology
• Rna Codon Chart
• Start Codon: Definition, Role in Translation, and Examples
• Starting Codon: Initiation of Protein Synthesis Explained

Sources

1. Molecular Determinants and Therapeutic Targeting of Stop Codon Readthrough in Eukaryotic Translation.
2. Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance.
3. A functional comparison of readthrough agent ELX-02 across a wide range of nonsense CFTR variants.
4. Mitochondrial translation termination, recycling, reinitiation, and rescue for in-frame and out-of-frame contexts.
5. RNA Cis-Elements Involved in Animal Virus Stop Codon Readthrough: Stop Codon Context and Downstream RNA Structures.
6. Defining the high-translational readthrough stop codon context.
7. The mRNA architecture of the translation termination site primes programmed stop codon readthrough events in Drosophila.
8. Evaluation of Readthrough Efficiency of Negamycin Derivatives against Nonsense Mutations in Muscular Dystrophy Genes.
9. Immunogenic implications of translational readthrough modulate the association of F8 nonsense mutations with inhibitors in Hemophilia A.
10. Glutamine codon-driven translational readthrough reveals context-dependent stop codon decoding fidelity.
11. Genomic stop codon scanning reveals quantitative principles of nonsense-mediated mRNA decay.
12. 2,6-Diaminopurine Induces ACTN3 Premature Termination Codon Readthrough.